These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

297 related items for PubMed ID: 21852468

  • 21. Fragment-based screening in tandem with phenotypic screening provides novel antiparasitic hits.
    Blaazer AR, Orrling KM, Shanmugham A, Jansen C, Maes L, Edink E, Sterk GJ, Siderius M, England P, Bailey D, de Esch IJ, Leurs R.
    J Biomol Screen; 2015 Jan; 20(1):131-40. PubMed ID: 25231971
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. In silico repositioning of approved drugs for rare and neglected diseases.
    Ekins S, Williams AJ, Krasowski MD, Freundlich JS.
    Drug Discov Today; 2011 Apr; 16(7-8):298-310. PubMed ID: 21376136
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Antichagasic activity of komaroviquinone is due to generation of reactive oxygen species catalyzed by Trypanosoma cruzi old yellow enzyme.
    Uchiyama N, Kabututu Z, Kubata BK, Kiuchi F, Ito M, Nakajima-Shimada J, Aoki T, Ohkubo K, Fukuzumi S, Martin SK, Honda G, Urade Y.
    Antimicrob Agents Chemother; 2005 Dec; 49(12):5123-6. PubMed ID: 16304182
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. [The therapeutic effect of allopurinol on American trypanosomiasis (Chagas disease) in CFW mice].
    Castrillón Rivera LE, García Fernández W, Pérez Gutiérrez C.
    Salud Publica Mex; 1984 Dec; 26(2):146-54. PubMed ID: 6427943
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Antiprotozoal Activity Profiling of Approved Drugs: A Starting Point toward Drug Repositioning.
    Kaiser M, Mäser P, Tadoori LP, Ioset JR, Brun R.
    PLoS One; 2015 Dec; 10(8):e0135556. PubMed ID: 26270335
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. [The chemotherapy of Chagas disease].
    Stoppani AO.
    Medicina (B Aires); 1999 Dec; 59 Suppl 2():147-65. PubMed ID: 10668258
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Isoxazolylnaphthoquinone effects on the growth of Trypanosoma cruzi.
    Amuchástegui PI, Moretti ER, Basso B, Sperandeo N, de Bertorello MM.
    Rev Argent Microbiol; 1990 Dec; 22(4):199-207. PubMed ID: 2129475
    [Abstract] [Full Text] [Related]

  • 34. Chagas disease: pushing through the pipeline.
    Clayton J.
    Nature; 2010 Jun 24; 465(7301):S12-5. PubMed ID: 20571548
    [No Abstract] [Full Text] [Related]

  • 35. Trypanocidal activity of extracts and fractions of Bertholletia excelsa.
    Campos FR, Januário AH, Rosas LV, Nascimento SK, Pereira PS, França SC, Cordeiro MS, Toldo MP, Albuquerque S.
    Fitoterapia; 2005 Jan 24; 76(1):26-9. PubMed ID: 15664458
    [Abstract] [Full Text] [Related]

  • 36. Vouching for access.
    Nat Med; 2016 Jul 07; 22(7):693. PubMed ID: 27387878
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Recognizing and meeting the challenge of Chagas disease in the USA.
    Bowling J, Walter EA.
    Expert Rev Anti Infect Ther; 2009 Dec 07; 7(10):1223-34. PubMed ID: 19968514
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.